Ranbaxy launches Caduet authorized generic
PRINCETON, N.J. — Days after its launch of a generic version of Pfizer’s cholesterol-lowering drug Lipitor, Ranbaxy Labs has launched a related drug as an authorized generic.
Ranbaxy announced the launch of an authorized generic version of Caduet (atorvastatin and amlodipine besylate). The drug is used to treat patients with high blood pressure and high cholesterol. Mylan launched a generic version of the drug on Thursday.
An authorized generic is a branded drug launched under its generic name at a reduced price, usually by a third-party company under contract with the original manufacturer, to coincide with the marketing of the Food and Drug Administration-approved generic.
Caduet had sales of $339 million during the 12-month period ended in September, according to IMS Health.
Pfizer’s Toviaz safe, effective in treating overactive bladder in elderly patients
NEW YORK — A drug made by Pfizer appears to work in treating symptoms of overactive bladder in elderly patients, according to results of a clinical trial released Monday.
Pfizer said that results of study A0221049 of the drug Toviaz (fesoterodine fumarate) worked better than placebo in reducing the number of urgency urinary incontinence episodes. The 12-week study enrolled 562 elderly people in the United States. The drug already has Food and Drug Administration approval for treating overactive bladder.
"For older individuals with overactive bladder, incontinence accompanied by urgency is the symptom that is most bothersome and embarrassing and greatly impacts their overall quality of life," said Steven Romano, Pfizer SVP and head of the medicines development group of the company’s global primary care business unit. "Importantly, this was the first study of any antimuscarinic agent to demonstrate efficacy and safety in the rapidly growing population of medically vulnerable seniors who struggle with overactive bladder."
Study tracks development, integration of MTM
WASHINGTON — The concept of medication therapy management has become more developed, and certain aspects of it have become established within the organizations providing and paying for it, according to a white paper published in the Journal of the American Pharmacists Association.
Researchers from pharmacy schools at the University of Minnesota, the University of Iowa, the University of Southern California and the University of Oklahoma collected data for "environmental scans" from MTM providers and payers throughout the United States using self-administered online surveys conducted between 2007 and 2010.
The study found a need to integrate MTM between organizations and patients serviced, between partnering organizations and between collaborating healthcare providers and that "a ‘channel of distribution’ is emerging in which organizational relationships and cost efficiencies will be important considerations in the near term." The researchers suggested that customer portfolio management and transaction cost economics would help to integrate MTM into the U.S. healthcare system.
Click here to see the white paper.